Skip to main content

Sarepta Therapeutics, Inc.

SRPT
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
SEC CIK
0000873303

No open-market purchases or sales by Sarepta Therapeutics, Inc. insiders were filed in the last 90 days; 326 institutions reported holding it in 13F filings for Q2 2026, worth $1.93B in total; no superinvestor holds it.

Key figures

Market capClose on Nov 13, 2026
$1.72B
Insider buysOpen market, last 90 days
0
Insider sellsOpen market, last 90 days
0
13F holdersQ2 2026, −17 vs. previous quarter
326
13F valueReported value at the end of Q2 2026
$1.93B
Superinvestors holdingAt the end of Q2 2026
0

Price chart

From SEC filings, in USD.

Revenue, FY2025
$2.20B
+15.6% year over year
Net income, FY2025
-$713.4M
−403.3% year over year
Free cash flow, FY2025
-$307.5M
No comparable prior period
Revenue, Q3 FY2026
$381.4M
−4.5% year over year

Revenue flow, FY2025

Green is profit; orange is costs, expenses and taxes. Percentages are shares of revenue.

Net loss for FY2025: $713.4M (32.5% of revenue).

Short interest

See short data

From FINRA, settlement date Oct 30, 2026.

Short interest
19.3M
Shares sold short
Change
−3.03M
−13.6% vs. previous
Days to cover
7.82
At average daily volume

Superinvestors holding SRPT, Q2 2026

Go to the superinvestors tab

No superinvestor reported holding SRPT at the end of Q2 2026.

Latest insider trades

See all insider trades

Open-market purchases and sales by Sarepta Therapeutics, Inc. insiders from Form 4, newest first.

Insider trades
Filed (ET)Trade dateFiling delayInsiderTransactionSharesAvg priceValueHolding changeFlags
Mar 13, 2026 (view filing)Mar 121 dayMayo StephenDirectorSSale−7.24K$17.02−$123.2K−80.4%1.76K after
Dec 18, 2025 (view filing)Dec 162 daysEstepan Ian MichaelChief Operating OfficerSSale−13.2K$22.31−$294.2K−6.4%193.3K after
Mar 13, 2025 (view filing)Mar 121 dayNicaise ClaudeDirectorSSale−2.49K$99.64−$248.2K−8.2%27.8K after
Dec 16, 2024 (view filing)Dec 124 daysWigzell Hans Lennart RudolfDirectorSSale−10.5K$124.84−$1.31M−31.5%22.8K after
Dec 6, 2024 (view filing)Dec 51 dayBoor Kathryn JeanDirectorSSale−1.64K$125.55−$205.4K−21.8%5.88K after
Sep 3, 2024 (view filing)Aug 304 daysEstepan Ian MichaelChief Financial OfficerSSale−5.99K$137.36−$822.1K−15.0%33.9K after
Aug 20, 2024 (view filing)Aug 164 daysChambers Michael AndrewDirectorPPurchase+37.0K$133.80+$4.96M+15.0%284.0K after3 lots
Jun 25, 2024 (view filing)Jun 25Same dayBrown Ryan EdwardEVP, General CounselSSale−39.0K$161.61−$6.30M−69.5%17.1K after7 lots10b5-1
Jun 25, 2024 (view filing)Jun 24-251 dayArif BilalChief Tech Ops OfficerSSale−11.8K$163.13−$1.92M−40.4%17.4K after6 lots10b5-1
May 6, 2024 (view filing)May 24 daysMurray DallanChief Customer OfficerSSale−3.63K$140.00−$508.9K−16.7%18.1K after10b5-1

Top 10 13F holders, Q2 2026

See all 326 holders

The largest institutional positions in Sarepta Therapeutics, Inc. at the end of Q2 2026; share changes are against Q1 2026.

Institutions holding SRPT in Q2 2026
InstitutionSharesValue% of portfolioChange in sharesAction
BlackRock, Inc.18,994,958$341.3M0.01%+4,239,681+28.7%Added
State Street Corp8,916,090$160.2M0.00%+2,302,776+34.8%Added
Vanguard Portfolio Management LLC8,377,470$150.5M0.01%+1,736,778+26.2%Added
Two Sigma Investments, LP4,598,735$82.6M0.06%+5,540+0.1%Added
Vanguard Capital Management LLC4,591,755$82.5M0.00%+13,520+0.3%Added
First Trust Advisors LP4,365,951$78.5M0.05%+230,163+5.6%Added
AQR Capital Management LLC4,325,689$76.9M0.03%−2,107,423−32.8%Reduced
Geode Capital Management, LLC2,771,758$49.8M0.00%+782,962+39.4%Added
Erste Asset Management GmbH2,568,945$45.5M0.35%−400,000−13.5%Reduced
Marshall Wace, LLP2,206,022$39.6M0.03%+1,480,954+204.3%Added

Holders of 5% or more of SRPT

See all 4 holders and filings

Holders whose latest Schedule 13D or 13G filing reports 5% or more of Sarepta Therapeutics, Inc..

Largest holders of SRPT from 13D and 13G filings
HolderLatest formStakeChangeFirst filedLatest filingFiling
BlackRock, Inc.13G/A15.80%16.6M shares+3.20 ppfrom 12.60%Jan 21, 20262 filingsJul 30, 2026SEC
Vanguard Portfolio Management LLC13G/A8.05%8.50M shares+1.62 ppfrom 6.43%Apr 29, 20262 filingsJul 31, 2026SEC
State Street Corp13G7.00%7.41M shares−1.40 ppfrom 8.40%Nov 10, 20253 filingsNov 10, 2026SEC
Vanguard Capital Management LLC13G5.11%5.37M sharesNewApr 30, 20261 filingApr 30, 2026SEC

3 members of Congress reported 11 trades in Sarepta Therapeutics, Inc. since 2020. Newest filings:

  1. Gilbert Ray Cisneros, Jr.

    House · CA · May 6, 2025

    Sell$1K-$15K

  2. Josh Gottheimer

    House · NJ · Aug 21, 2023

    Buy$1K-$15K

  3. Josh Gottheimer

    House · NJ · Jul 11, 2023

    Sell$1K-$15K

  4. Daniel S. Goldman

    House · NY · May 19, 2023

    Sell$15K-$50K

  5. Josh Gottheimer

    House · NJ · Apr 20, 2023

    Buy$1K-$15K